OncoSil Medical Ltd

As of June 30, 2026, OncoSil Medical Ltd carries a market capitalization of 21.93M, placing it among publicly traded companies globally. Its enterprise value stands at 15.47M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

OncoSil Medical Ltd's next confirmed earnings release is scheduled for March 2, 2027.

As of June 30, 2026, OncoSil Medical Ltd has 30.89M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 9.54, and the price-to-book ratio stands at 4.39.

These figures are as of June 30, 2026. The EV/Sales ratio of 9.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 15.47M versus a market cap of 21.93M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, OncoSil Medical Ltd maintains a current ratio of 1.77, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.30, indicating conservative leverage, while an interest coverage ratio of -1,095.54 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, OncoSil Medical Ltd posted a negative return on equity (ROE) of -268.15, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -124.40, reflecting losses generated across the asset base.

As of the close on October 22, 2026, OncoSil Medical Ltd's stock has declined approximately 48.90% over the past 52 weeks. The 50-day moving average sits at 0.95, while the 200-day moving average is 0.79.

Over the twelve months ended June 30, 2026, OncoSil Medical Ltd generated 1.68M in revenue and converted that into -10.86M in net income, yielding earnings per share of -0.48. EBITDA reached -14.42M, while operating income came in at -14.48M.

As of June 30, 2026, OncoSil Medical Ltd holds 6.48M in cash and equivalents against 14,782.00 in total debt, resulting in a net debt position of -6.48M. Total book value stands at 5.00M, with working capital of 4.07M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, OncoSil Medical Ltd posted a gross margin of -39.90, reflecting its pricing power and cost economics. The operating margin of -859.17 and net profit margin of -644.53 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -54.09, meaning OncoSil Medical Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

OncoSil Medical Ltd's most recent stock split took place on February 5, 2026 with a 174:175 split ratio.

As of June 30, 2026, OncoSil Medical Ltd has an Altman Z-Score of -17.45, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.